Related Experiment Video
Updated: Aug 5, 2026
Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
Engineering Oncolytic Measles Virus with MG53 Couples Pyroptotic Tumor Killing with Immune Microenvironment
Abstract:
Lung cancer is the leading cause of cancer-related mortality worldwide, with only approximately 30% of patients benefiting from current immune checkpoint immunotherapy. Oncolytic virotherapy offers a promising strategy to overcome this resistance; however, achieving both potent tumor cytotoxicity and robust antitumor immune activation remains a major challenge. Here, we engineered oncolytic measles virus expressing the tumor suppressor MG53 (TRIM72), designated rMeV-MG53, and evaluated its therapeutic potential against non-small cell lung cancer (NSCLC). rMeV-MG53 retained replication kinetics comparable to parental MeV while driving significantly greater cytotoxicity than an unarmed control in NSCLC cells. Mechanistically, MG53 arming amplified caspase-3-dependent apoptosis and potentiated Gasdermin E (GSDME) cleavage, engaging GSDME-mediated pyroptosis as a key tumor-killing mechanism; pharmacological inhibition confirmed caspase-dependent apoptosis as the initiating event leading to pyroptosis, while excluding necroptosis and ferroptosis as significant contributors to rMeV-MG53-induced cytotoxicity. MG53 overexpression induced an intrinsic pro-inflammatory transcriptional signature enriched for TNF, NF-κB, and IL-17 signaling, and rMeV-MG53 elicited significantly stronger type I interferon and pro-inflammatory cytokine induction than the unarmed control. In an immunocompetent, MeV-permissive syngeneic NSCLC model, intratumoral rMeV-MG53 achieved superior tumor growth inhibition, amplified caspase-3/GSDME pyroptosis, selectively upregulated Cxcl10 , Ifng , and Il1b , and drove robust CD8⁺ T-cell and Granzyme B⁺ effector infiltration. This immune remodeling was accompanied by compensatory PD-L1 upregulation, and combining rMeV-MG53 with anti-PD-L1 blockade achieved the strongest tumor suppression of all treatment groups. These findings establish MG53-armed oncolytic MeV as a strategy coupling GSDME-mediated pyroptosis with antitumor immune remodeling to sensitize immune-resistant NSCLC to checkpoint immunotherapy.
Insights
Engineered oncolytic measles virus (MeV) expressing MG53 enhances cancer cell killing via pyroptosis and boosts anti-tumor immunity. Combining this with checkpoint blockade therapy shows promise for treating non-small cell lung cancer (NSCLC).
Area of Science:
- Oncology
- Virology
- Immunology
Background:
- Lung cancer is a leading cause of cancer mortality globally.
- Current immune checkpoint immunotherapy benefits only about 30% of patients.
- Oncolytic virotherapy is a promising strategy to overcome immunotherapy resistance.
Purpose of the Study:
- To engineer an oncolytic measles virus (MeV) expressing the tumor suppressor MG53 (rMeV-MG53).
- To evaluate the therapeutic potential of rMeV-MG53 against non-small cell lung cancer (NSCLC).
- To investigate the mechanisms of tumor cell killing and immune activation induced by rMeV-MG53.
Main Methods:
- Engineered oncolytic measles virus (MeV) expressing MG53 (rMeV-MG53).
- Evaluated cytotoxicity in NSCLC cells and in a syngeneic NSCLC mouse model.
- Investigated mechanisms of cell death (apoptosis, pyroptosis, necroptosis, ferroptosis) and immune responses.
- Combined rMeV-MG53 with anti-PD-L1 blockade therapy.
Main Results:
- rMeV-MG53 demonstrated enhanced cytotoxicity against NSCLC cells via MG53-amplified apoptosis and GSDME-mediated pyroptosis.
- rMeV-MG53 induced a pro-inflammatory transcriptional signature and stronger cytokine induction.
- In vivo, rMeV-MG53 inhibited tumor growth, promoted pyroptosis, upregulated immune markers, and increased CD8+ T-cell infiltration.
- Combination therapy with anti-PD-L1 blockade achieved superior tumor suppression.
Conclusions:
- MG53-armed oncolytic MeV effectively kills NSCLC cells through pyroptosis and enhances anti-tumor immunity.
- This strategy sensitizes immune-resistant NSCLC to checkpoint immunotherapy.
- rMeV-MG53 represents a promising therapeutic approach for NSCLC treatment.
